Similarly, miR-331-3p inhibits the proliferation and metastasis of NSCLC cells by targeting ErbB2 and VAV2 through the Rac1/PAK1/β-catenin axis [26]. Here, ERBB2 is linked to non-small cell lung carcinoma.